Neuroleptic Malignant Syndrome (NMS): What are the Genetic Factors?

Lazarus A. The neuroleptic malignant syndrome: a review. Can J Psychiatry 1986; 31: 670–674.

Burke R.E. , Fahn S. , Mayeux R. , Weinberg H. , Louis K. , Willner J.H. Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington's disease. Nuerology (NY) 1981; 31: 1022–1026.

Nelson T. , Flewellen E. The malignant hyperthermia syndrome. N Eng J Med 1983; 309: 416–418.

Tollefsong Tae-Yull Chlorpromazine induced neuroleptic malignant syndrome and its response to Diazepam. Biol Psychiatry 1983; 18: 1441–1448.

Caroff S. , Rosenberg H. , Gerber J.C. Malignant hyperthermia susceptibility in neuroleptic malignant syndrome. Presented at the 138th annual meeting of the American Psychiatric Association, Dallas, Texas, May 18–24, 1985.